European Journal of Organic Chemistry · 2015 · 15 citations · 29 references
PharmacyMedicinal ChemistryPharmacologyCatalysisDrug DiscoverySynthetic Medicinal ChemistryEnzyme InhibitionHypertension PharmacotherapyDirect Renin InhibitorsEnantioselective SynthesisRenin-angiotensin-aldosterone System InhibitorsStereoselective Reaction Design
Abstract Aliskiren is the first‐in‐class orally active direct renin inhibitor. It was approved in 2007 for the treatment of hypertension. We have designed a new strategy for the convergent synthesis of aliskiren that involves a catalytic stereoselective nitroaldol reaction as the key step. A new enantiopure nitroalkane (synthon A 1 ), prepared in only three steps from a commercially available enantiopure 2‐(arylmethyl)‐3‐methyl butanol derivative, was successfully used in a copper‐catalysed Henry reaction to give a nitrolactone intermediate in which the correct configuration for the final product was established at all four stereocentres. Nitro‐group reduction, Boc‐protection of the resulting amine, aminolysis of the lactone with 3‐amino‐2,2‐dimethylpropionamide, and finally Boc‐deprotection led to the enantiopure renin inhibitor aliskiren.
29
Catalytic asymmetric Henry reaction
Joshodeep Boruwa, Naminita Gogoi, Partha Pratim Saikia et al. · Tetrahedron Asymmetry · 2006 · 422 citations
Yirong Zhou, Junfang Dong, Fang‐Lin Zhang et al. · The Journal of Organic Chemistry · 2010 · 136 citations